Identifying the earliest virus-specific T cell responses during acute HIV-1 infection and the regions of HIV-1 targeted by these responses represents a critical component in the understanding of HIV-1 pathogenesis and the guidance of HIV-1 vaccine design. The Immunology Core will perform standard assays of HIVspecific adaptive immunity on all subjects with primary HIV-1 infection enrolled in this program and will enter these data into the overall database. Furthermore, the Core will provide access to multiparameter flow cytometers and biohazard cell sorting facilities to perform the experiments described in the individual projects. The Immunology Core will implement strict quality control mechanisms to ensure that these assays are performed following defined Standard Operating Procedures (SOP). The data from the characterization of the breadth, magnitude and specificity of the HIV-1-specific T cell response in acute HIV-1 infection generated by the Immunology Core will provide the baseline immunology data to select individual study subjects for the proposed specific studies of viral sequence evolution (Project 3), antigen processing and T cell function (Project 2). Furthermore, the parallel studies of adaptive and innate immunity (Project 1) will allow for the analysis of T cell function in the context of innate immune function. The proposed assays will incorporate a newly designed set of overlapping HIV-1 peptides spanning the entire expressed clade B consensus sequence, as well as all minor variants present in at least 5 -10% of the published HIV-1 clade B sequences in the Los Alamos National Database (

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI074415-05
Application #
8574938
Study Section
Special Emphasis Panel (ZAI1-IPG-A (M2))
Project Start
2008-09-26
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$361,781
Indirect Cost
$157,385
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Scully, Eileen P; Lockhart, Ainsley; Garcia-Beltran, Wilfredo et al. (2016) Innate immune reconstitution with suppression of HIV-1. JCI Insight 1:e85433
Blashill, Aaron J; Tomassilli, Julia; Biello, Katie et al. (2016) Body Dissatisfaction Among Sexual Minority Men: Psychological and Sexual Health Outcomes. Arch Sex Behav 45:1241-7
Carlson, Jonathan M; Du, Victor Y; Pfeifer, Nico et al. (2016) Impact of pre-adapted HIV transmission. Nat Med 22:606-13
Palmer, Christine D; Romero-Tejeda, Marisol; Sirignano, Michael et al. (2016) Naturally Occurring Subclinical Endotoxemia in Humans Alters Adaptive and Innate Immune Functions through Reduced MAPK and Increased STAT1 Phosphorylation. J Immunol 196:668-77
Scully, Eileen; Lockhart, Ainsley; Huang, Lisa et al. (2016) Elevated Levels of Microbial Translocation Markers and CCL2 Among Older HIV-1-Infected Men. J Infect Dis 213:771-5
Sun, Hong; Kim, Dhohyung; Li, Xiaodong et al. (2015) Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy. J Virol 89:11284-93
Martins, Mauricio A; Tully, Damien C; Cruz, Michael A et al. (2015) Vaccine-Induced Simian Immunodeficiency Virus-Specific CD8+ T-Cell Responses Focused on a Single Nef Epitope Select for Escape Variants Shortly after Infection. J Virol 89:10802-20
Palmer, Christine D; Tomassilli, Julia; Sirignano, Michael et al. (2014) Enhanced immune activation linked to endotoxemia in HIV-1 seronegative MSM. AIDS 28:2162-6
Vaidya, Sagar A; Korner, Christian; Sirignano, Michael N et al. (2014) Tumor necrosis factor ? is associated with viral control and early disease progression in patients with HIV type 1 infection. J Infect Dis 210:1042-6
Buzon, Maria J; Martin-Gayo, Enrique; Pereyra, Florencia et al. (2014) Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol 88:10056-65

Showing the most recent 10 out of 44 publications